Umbilical cord-derived Wharton's jelly for regenerative medicine applications in orthopedic surgery: a systematic review protocol
- PMID: 33176838
- PMCID: PMC7659052
- DOI: 10.1186/s13018-020-02067-w
Umbilical cord-derived Wharton's jelly for regenerative medicine applications in orthopedic surgery: a systematic review protocol
Abstract
Background: Musculoskeletal injuries and conditions affect millions of individuals. These ailments are typically managed by immobilization, physiotherapy, or activity modification. Regenerative medicine has experienced tremendous growth in the past decades, especially in musculoskeletal medicine. Umbilical cord-derived Wharton's jelly is an exciting new option for such therapies. Wharton's jelly is a connective tissue located within the umbilical cord largely composed of mesenchymal stem cells and extracellular matrix components, including collagen, chondroitin sulfate, hyaluronic acid, and sulfated proteoglycans. Wharton's jelly is a promising and applicable biologic source for orthopedic regenerative application.
Methods: A systematic search will be conducted in PubMed, ScienceDirect, and Google Scholar databases of English, Italian, French, Spanish, and Portuguese language articles published to date. References will be screened and assessed for eligibility by two independent reviewers as per PRISMA guidelines. Articles will be considered without exclusion to sex, activity, or age. Studies will be included if they used culture-expanded, mesenchymal stem/stromal cells of mesenchymal stem cells and/or connective tissue obtained from Wharton's jelly. Studies will be excluded if Wharton's jelly is not the sole experimental examined cell type. Placebos, conventional non-operative therapies including steroid injections, exercise, and NSAIDs will be compared. The study selection process will be performed independently by two reviewers using a reference software. Data synthesis and meta-analysis will be performed separately for clinical and pre-clinical studies.
Discussion: The results will be published in relevant peer-reviewed scientific journals. Investigators will present results at national or international conferences.
Trial registration: The protocol was registered on PROSPERO international prospective register of systematic reviews prior to commencement, CRD42020182487 .
Keywords: Musculoskeletal injuries; PRISMA; Regenerative medicine; Umbilical cord; Wharton’s jelly.
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol.J Orthop Surg Res. 2022 Jun 11;17(1):307. doi: 10.1186/s13018-022-03197-z. J Orthop Surg Res. 2022. PMID: 35690774 Free PMC article.
-
Umbilical Cord-Derived Wharton's Jelly for Regenerative Medicine Applications: A Systematic Review.Pharmaceuticals (Basel). 2021 Oct 27;14(11):1090. doi: 10.3390/ph14111090. Pharmaceuticals (Basel). 2021. PMID: 34832872 Free PMC article. Review.
-
Umbilical cord-derived Wharton's jelly for treatment of knee osteoarthritis: study protocol for a non-randomized, open-label, multi-center trial.J Orthop Surg Res. 2021 Feb 18;16(1):143. doi: 10.1186/s13018-021-02300-0. J Orthop Surg Res. 2021. PMID: 33602286 Free PMC article. Clinical Trial.
-
Umbilical cord-derived Wharton's jelly for regenerative medicine applications.J Orthop Surg Res. 2020 Feb 13;15(1):49. doi: 10.1186/s13018-020-1553-7. J Orthop Surg Res. 2020. PMID: 32054483 Free PMC article.
-
Wharton's Jelly stem cells: future clinical applications.Placenta. 2011 Oct;32 Suppl 4:S311-5. doi: 10.1016/j.placenta.2011.06.010. Epub 2011 Jul 6. Placenta. 2011. PMID: 21733573 Review.
Cited by
-
Allogenic perinatal tissue for musculoskeletal regenerative medicine applications: a systematic review protocol.J Orthop Surg Res. 2022 Jun 11;17(1):307. doi: 10.1186/s13018-022-03197-z. J Orthop Surg Res. 2022. PMID: 35690774 Free PMC article.
-
Allogenic Amniotic Tissue for Treatment of Knee and Hip Osteoarthritis.Pharmaceuticals (Basel). 2022 Mar 26;15(4):404. doi: 10.3390/ph15040404. Pharmaceuticals (Basel). 2022. PMID: 35455401 Free PMC article.
-
Characterization of chondroitin sulfate in stem cells derived from umbilical cord blood in rats.PLoS One. 2022 Jan 25;17(1):e0262854. doi: 10.1371/journal.pone.0262854. eCollection 2022. PLoS One. 2022. PMID: 35077481 Free PMC article.
-
Umbilical Cord-Derived Wharton's Jelly for Regenerative Medicine Applications: A Systematic Review.Pharmaceuticals (Basel). 2021 Oct 27;14(11):1090. doi: 10.3390/ph14111090. Pharmaceuticals (Basel). 2021. PMID: 34832872 Free PMC article. Review.
-
Cell-free stem cell-derived extract formulation for treatment of knee osteoarthritis: study protocol for a preliminary non-randomized, open-label, multi-center feasibility and safety study.J Orthop Surg Res. 2021 Aug 20;16(1):514. doi: 10.1186/s13018-021-02672-3. J Orthop Surg Res. 2021. PMID: 34416898 Free PMC article.
References
-
- Navani A, Manchikanti L, Albers SL, Latchaw RE, Sanapati J, Kaye AD, et al. Responsible, safe, and effective use of biologics in management of low back pain: American Society of Interventional Pain Physicians (ASIPP) guidelines. Pain Physician. 2019;22(1 s):S1–S74. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous